PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. New England Journal Of Medicine 2022, 386: 2363-2376. PMID: 35660797, PMCID: PMC9492301, DOI: 10.1056/nejmoa2201445.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapyDNA Mismatch RepairHumansNeoadjuvant TherapyNeoplasm StagingNeoplasms, Second PrimaryProgrammed Cell Death 1 ReceptorProspective StudiesRectal NeoplasmsRectumTreatment OutcomeConceptsAdvanced rectal cancerClinical complete responsePD-1 blockadeRectal cancerComplete responseSingle-agent PD-1 blockadeAnti-PD-1 monoclonal antibodyProspective phase 2 studyMismatch repair-deficient colorectal cancersDeath-1 blockadePrimary end pointCase of progressionEvidence of tumorPathological complete responsePhase 2 studyDigital rectal examinationDuration of responseMismatch repair deficientMagnetic resonance imagingNeoadjuvant chemotherapyUndergone surgeryAdverse eventsCheckpoint blockadeMetastatic diseaseSurgical resection